Literature DB >> 8834768

Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors.

H Friess1, P Berberat, M Schilling, J Kunz, M Korc, M W Büchler.   

Abstract

Molecular alterations play a key role in the pathogenesis of gastrointestinal cancers. In the present paper we describe relevant molecular alterations in human pancreatic adenocarcinomas. Overexpression of growth factor receptors (EGF receptor, c-erbB2, c-erbB3, TGF beta receptor I-III), growth factors (EGF, TGF alpha, TGF beta-1-3, aFGF, bFGF), adhesion molecules (ICAM-1, ELAM-1) and gene mutations (p53, K-ras, DCC, APC) are present in a significant number of these tumors. These changes stimulate tumor growth and enhance the metastatic behavior of pancreatic cancer cells and thereby may contribute to shorter postoperative survival following tumor resection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834768     DOI: 10.1007/bf00202070

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  111 in total

1.  Loss of growth inhibitory activity of TGF-beta toward normal human mammary epithelial cells grown within collagen gel matrix.

Authors:  K Takahashi; K Suzuki; T Ono
Journal:  Biochem Biophys Res Commun       Date:  1990-12-31       Impact factor: 3.575

2.  Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha.

Authors:  M Korc; J E Finman
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

3.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma.

Authors:  M Tada; M Omata; S Kawai; H Saisho; M Ohto; R K Saiki; J J Sninsky
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

6.  A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.

Authors:  M Büchler; H Friess; K H Schultheiss; C Gebhardt; R Kübel; K H Muhrer; M Winkelmann; T Wagener; R Klapdor; M Kaul
Journal:  Cancer       Date:  1991-10-01       Impact factor: 6.860

Review 7.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

8.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

9.  Recycling of epidermal growth factor in a human pancreatic carcinoma cell line.

Authors:  M Korc; B E Magun
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  22 in total

Review 1.  Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma.

Authors:  Felix J Hüttner; Christina Fitzmaurice; Guido Schwarzer; Christoph M Seiler; Gerd Antes; Markus W Büchler; Markus K Diener
Journal:  Cochrane Database Syst Rev       Date:  2016-02-16

2.  Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer.

Authors:  H Friess; Z Lu; A Andrén-Sandberg; P Berberat; A Zimmermann; G Adler; R Schmid; M W Büchler
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

3.  bax, but not bcl-2, influences the prognosis of human pancreatic cancer.

Authors:  H Friess; Z Lu; H U Graber; A Zimmermann; G Adler; M Korc; R M Schmid; M W Büchler
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

4.  Akt kinase mediates the prosurvival effect of smoking compounds in pancreatic ductal cells.

Authors:  Chang-Hwan Park; In-Seok Lee; Paul Grippo; Stephen J Pandol; Anna S Gukovskaya; Mouad Edderkaoui
Journal:  Pancreas       Date:  2013-05       Impact factor: 3.327

Review 5.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas.

Authors:  H Friess; L Wang; Z Zhu; R Gerber; M Schröder; A Fukuda; A Zimmermann; M Korc; M W Büchler
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

7.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis.

Authors:  Christine M Ardito; Barbara M Grüner; Kenneth K Takeuchi; Clara Lubeseder-Martellato; Nicole Teichmann; Pawel K Mazur; Kathleen E Delgiorno; Eileen S Carpenter; Christopher J Halbrook; Jason C Hall; Debjani Pal; Thomas Briel; Alexander Herner; Marija Trajkovic-Arsic; Bence Sipos; Geou-Yarh Liou; Peter Storz; Nicole R Murray; David W Threadgill; Maria Sibilia; M Kay Washington; Carole L Wilson; Roland M Schmid; Elaine W Raines; Howard C Crawford; Jens T Siveke
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

Review 9.  Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer.

Authors:  Chi-Hin Wong; You-Jia Li; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

10.  Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

Authors:  Bryan A Faller; Barbara Burtness
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.